Medexus expects public reimbursement for its joint-disease drug to roll out 'almost immediately'

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive that price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH) in Canada are complete.

d’Entremont says the public reimbursement is expected to roll out in a few of the Canadian provinces almost immediately and over the coming months, and should help Medexus expand sales and market access.

immediately'